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In the National Cancer Institute’s Second International Workshop on the Biology, Prevention, and Treatment of
Relapse after Hematopoietic Stem Cell Transplantation, the Scientiﬁc/Educational Session on Autologous
Transplantation addressed the role of novel agents and immunomodulatory strategies in management of
relapse after autologous hematopoietic stem cell transplantation (AHSCT). Concepts were illustrated through
in-depth discussion of multiple myeloma, with broader discussion of areas relevant for relapse of other
malignancies as well as in the setting of allogeneic transplantation. Dr. Hari provided an overview of the
epidemiology of relapse after AHSCT in multiple myeloma, addressing clinical patterns, management impli-
cations, and treatment options at relapse, highlighting the implications of novel therapeutic agents in initial,
maintenance, and relapse treatment. Dr. Avigan discussed current concepts in tumor vaccine design, including
whole cell and antigen-speciﬁc strategies, use of an AHSCT platform to reverse tumor-associated immuno-
suppression and tolerance, and combining vaccineswith immunomodulatory agents to promote establishment
of durable antitumor immunity. Dr. Hsu reviewed the immunogenetics of natural killer (NK) cells and general
NK biology, the clinical importance of autologous NK activity (eg, lymphoma and neuroblastoma), the impact of
existing therapies on promotion of NK cell activity (eg, immunomodulatory drugs, monoclonal antibodies), and
strategies for enhancing autologous and allogeneic NK cell effects through NK cell gene proﬁling.
Published by Elsevier Inc. on behalf of American Society for Blood and Marrow Transplantation.INTRODUCTION Strategies discussed parallels between AHSCT and AlloSCT
Gains in understanding the biologic effects of antitumor
therapy on the immune system yield important insights into
the mechanisms of tumor control and relapse after both
allogeneic stem cell transplantation (AlloSCT) and autologous
hematopoietic stem cell transplantation (AHSCT). In the
National Cancer Institute’s Second InternationalWorkshop on
the Biology, Prevention, and Treatment of Relapse after
Hematopoietic Stem Cell Transplantation, the Scientiﬁc/
Educational Session on Autologous Transplantation: Relapse
Prevention Using Novel Agents and Immunomodulatorydgments on page 1667.
equests: Nancy M. Hardy, MD, Experi-
ology Branch, National Cancer Institute/
enter Drive, Hatﬁeld Clinical Research
D 20892.
ih.gov (N.M. Hardy).
blished by Elsevier Inc. on behalf of American
13.08.011platforms with respect to relapse biology, prevention, and
treatment.Discussionofmultiplemyeloma (MM) relapse after
autologous transplantation illustrated the evolution of disease
characteristics after SCT, including the impact of the novel,
immunomodulatory agents that are now standard therapies
for MM before and after SCT. Immunomodulatory relapse
interventions were discussed, including use of vaccine-based
tumor targeting and exploitation of natural killer (NK) cell
biology to achieve optimal treatment outcomes.
I. RELAPSE AFTER AHSCT: THE MM PARADIGM
MM epitomizes many of the challenges posed by relapse
after SCT, with disease being the major cause of treatment
failure and rapid evolution of diagnostic and therapeutic
tools yielding tectonic shifts in the clinical landscape. The
following discussion of MM relapse after AHSCT provides
a paradigm for considering new approaches to preventionSociety for Blood and Marrow Transplantation.
Figure 2. Salvage second AHSCT for relapsed MM. Kaplan-Meier estimates of
OS after salvage second AHSCT for MM relapse, stratiﬁed by time to relapse
after ﬁrst AHSCT (<36 mo versus >36 mo), as reported to the CIBMTR [31].
D. Avigan et al. / Biol Blood Marrow Transplant 19 (2013) 1661e16691662and treatment of post-transplant relapse, approaches that
could extend to AlloSCT as well.
Major advances in MM drug therapy have led to superior
induction regimens, better AHSCT outcomes, and improved
survival after relapse [1]. Many patients now receive upfront
AHSCT with sensitive disease in complete remission (CR) or
very good partial remission and achieve higher rates of post-
transplantation CR, leading to superior progression-free
survival (PFS). Novel agents, such as immunomodulatory
drugs (IMiDs; thalidomide derivatives) and proteasome
inhibitors (PIs), have also improved survival after post-
transplantation progression [2]. Analysis of the Center for
International Blood and Marrow Transplant Research
(CIBMTR) registry data on more than 20,000 recipients of
upfront AHSCT for MM demonstrated improved 5-year
overall survival (OS) over time, including major gains in
post-transplantation relapse survival [3] (Figures 1 and 2).Diagnosing Relapse
Deﬁning relapse of MM post-transplantation is compli-
cated; persistence or recurrence of a myeloma clone detected
biochemically does not reliably predict clinical progression
after either AHSCT or AlloSCT [4]. Even absent CR, a signiﬁ-
cant proportion of patients treated with AHSCT will achieve
prolonged periods of a monoclonal gammopathy of unde-
termined signiﬁcance (MGUS-)-like” state. Additionally,
biochemical monitoring may miss progression after AHSCT;
clinical relapse frequently involves a nonsecretory compo-
nent and aggressive relapse often presents as extramedullary
disease, with discordance between imaging (eg, magnetic
resonance imaging and positron emission tomography) andFigure 1. CIBMTR analysis of survival trends over time after AHSCT for MM.
(A) Kaplan-Meier estimates of OS after AHSCT for patients who received
AHSCT between 1995-1999, 2000-2004, and 2005-2010. (B) OS after myeloma
relapse/progression after AHSCT as reported to the CIBMTR for patients who
relapsed between 1995-1999, 2000-2004, and 2005-2010 [3].biochemical disease parameters [5]. These distinctions have
been addressed in few published studies. Although current
guidelines distinguish biochemical versus clinical progres-
sion,most prior studies used biochemical criteria [6], limiting
interpretation of relapse presentation, incidence, and
outcome of AHSCT relapse by relying on traditional criteria.
Clinical Behavior of Relapsed MM
Relapsed myeloma differs from newly diagnosed disease
in clinical behavior and biologic correlates [7]. OS from ﬁrst
relapse is generally shorter than the progression-free
interval after transplantation, although distinct clinical
patterns are evident: relapse after early AHSCT (3 prior
regimens) with expected sensitivity to IMiD or PI therapy,
relapse or transplantation-refractory disease resistant to
prior IMiD/PI therapy (“double-refractory disease”), and
primary-refractory disease. Retrospective data show
outcomes of patients with AHSCT relapse have improved
over time, coincident with the introduction of novel agents
[8]. The presentation of clinical relapse is similarly variable
and inﬂuenced by monitoring methods and frequency. In
a Spanish registry study, two thirds of AHSCT recipients
developed “classical” MM relapse, with increase in M-spike
and organ impairment. Extramedullary disease and secondary
plasma cell leukemia signiﬁed relapse in 14% and 2%, re-
spectively, whereas 18% presented initially with isolated
biochemical relapse [9].
In patients relapsing in the era preceding novel agents
(1985 to 1998), Kumar et al. [8] reported a median OS of
17 months, with 84% dying by 5 years. Coincident with the
introduction of IMiD and PI therapies, survival has improved
for patients with ﬁrst relapse after 2000, compared with
those diagnosed with initial relapse before that year (23.9
versus 11.8 months, respectively) [1]. A recent international
survey suggested a response rate of 58% to ﬁrst-salvage
treatment after AHSCT, with PFS and OS rates of 13 and
25 months, respectively (with diminishing response rates to
successive salvage regimens) [10]. Consistent with the
contribution of modern agents, the addition of bortezomib to
thalidomide/dexamethasone therapy appears to improve
outcomes (median OS of 3 years) [11], although the beneﬁt
does not seem to extend to those with double-refractory MM
[12]. Current practice and ongoing investigations integrate
novel agents into upfront MM therapy and AHSCT consoli-
dation and/or maintenance; the impact of these changes on
AHSCT outcomes and survival after relapse remains to be
deﬁned. However, the poor outcomes seen in the double-
refractory setting suggest that effective therapy for relapse
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may be difﬁcult to achieve with available agents.
Long-Term Survivorship
Even in the preenovel agent era, some patients had pro-
longed CR or nonprogressive partial remission (MGUS-like
clonal persistence). A 12-year disease-free interval fromAHSCT
has been suggested as the threshold after which clinical
progression is rare [13] and is often used to deﬁne the “cure
fraction” or “operationally cured” forMMtherapy. In their Total
Therapy1 tandemAHSCTtrial (1989to1998),Barlogieet al. [14]
showed 33% and 17% OS at 10 and 15 years, respectively, with
15%and7%event-freesurvivaland18%and12%maintainingCR.
CIBMTR data suggest that at 10 years, 25% to 29% of AHSCT
recipients are alive and 10% to 15% are progression-free [15].
Long-term PFS may reﬂect immune-mediated disease
control [16]. Superior immune reconstitution has been
observed in AHSCT recipients with long-term disease-free
survival [17,18] who demonstrate increased numbers of CD8þ
T cells, NK cells, dendritic cells (DCs), and normal plasma
cells. Further, regulatory T cells were found to be reduced,
potentially favoring the action of cytotoxic cells, recovery of B
cell production, and homing of normal plasma cells into the
bone marrow [19].
Predicting Relapse Risk
With the adoption of increasingly stringent response
criteria, a clear association has emerged between CR and
event-free survival and OS after AHSCT. Because many
recipients with clinical CR ultimately relapse, minimal
residual disease (MRD) monitoring with increasingly
sensitive PCR-based and multiparameter ﬂow cytometry
methods of detecting clonal plasma cell populations is
being evaluated to identify risk of relapse [20]. PCR-based
methods are highly sensitive (104 to 106), but informa-
tive sequences cannot readily identify the myeloma clone
for a substantial minority of patients. Although initial
studies of PCR methods found molecular evidence of
myeloma in nearly all patients with clinical CR, retrospec-
tive studies of patients who had achieved immunoﬁxation-
deﬁned CR after AlloSCT identiﬁed molecular CR in one half
[21], more molecular CR after treatment with AlloSCT than
AHSCT [22], and that molecular CR predicted less relapseTable 1
Maintenance/Consolidation Strategies after AHSCT: Recent Studies
Study Agent C
CALGB 100104/CTN
McCarthy P et al., N Engl J Med
2012;366:1770
Maintenance: lenalidomide versus
placebo
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IFM Study
Attal M et al., N Engl J Med
2012;366:1782
Consolidation/maintenance:
lenalidomide  2 mo/
lenalidomide versus placebo
P
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HOVON 65-GMMG-HD4
Sonneveld et al., J Clin Oncol
2012;30:2946
Induction/maintenance:
bortezomib-based induction/
maintenance versus conventional
chemotherapy induction and
thalidomide maintenance
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MRC Myeloma IX Trial
Morgan G et al., Blood 2012;119:7
Maintenance: thalidomide versus
none after intensive or non-
intensive upfront therapy
5
P
si
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TTP indicates time-to-progression; CALGB, Cancer and Leukemia Group B; CTN,
Myeloma Foundation; HOVON 65-GMMG-HD4, Dutch-Belgian Hemato-Oncology
Medical Research Council; FISH, ﬂuorescent in situ hybridization.and longer relapse-free survival [23]. Although somewhat
less sensitive than PCR (104), multiparameter ﬂow
cytometry can distinguish clonal from normal bone marrow
plasma cells in nearly all patients with MM [24]; multipa-
rameter ﬂow cytometry detection of MRD at day 100 after
AHSCT has been shown to predict relapse and survival
[25,26]. Although both PCR and multiparameter ﬂow
cytometry assessment of MRD demonstrate that deeper
levels of remission after therapy for MM correlate with
superior PFS, no level of remission that equates to a cure has
been deﬁned to date, and MRD monitoring remains avail-
able only in the research setting. Nonetheless, MRD tech-
niques validated in the AHSCT setting [27] may identify
patients whose relapse risk warrants additional mainte-
nance or immune-based intervention post-transplant.
Recent advances in gene sequencing technology have
opened exciting new avenues of cancer investigation with
potential implications for deﬁning relapse risk [16]. Analyses
of the genomic changes that underlie disease progression
demonstrate distinct patterns of clonal dynamics [27,28]. In
patients with high-risk MM, for example, disease is charac-
terized by clonal heterogeneity at diagnosis and by genomic
instability, likely determinants of evolution toward increas-
ingly aggressive disease. How to integrate and target
genomic complexity therapeutically should be a high priority
for future research.
Maintenance and Consolidation Strategies to Prevent
Relapse
Efforts to improve outcomes after AHSCT include consoli-
dation (short-course therapy applied to eradicate residual
disease) or maintenance (prolonged lower-intensity therapy
applied to prevent relapse). Although improving PFS,
prevention strategies have not consistently resulted in OS
beneﬁts; further, the effect of these strategies on “operational
cure” rates are undetermined (Table 1). Although there
appears to be little doubt that deeper remissions yield PFS
beneﬁt, many issues regarding preventive interventions
remain unresolved: the optimal regimen, schedule, and
durationof preventive therapy; inwhompreventive therapy is
unnecessary or, perhaps, harmful; the potential for emergence
of resistant clones; and how preventive therapy compares
with early retreatment in terms of OS and quality of life.omment Median PFS/TTP in Superior Arm
avored lenalidomide: TTP 46 mo
ersus 27 mo
verall mortality: 15% versus 23%
-yr OS: 88% versus 80%
Lenalidomide TTP 46 mo
FS favored lenalidomide: 41 mo
ersus 23 mo
o survival beneﬁt: >70% in both
roups alive at 4 years
Lenalidomide PFS 41 mo
ole of maintenance difﬁcult to
parate
ortezomib arm superior (PFS 35
o versus 28 mo; OS beneﬁt in
ultivariate models)
Bortezomib induction/maintenance
PFS 35 mo
2% stopped thalidomide
FS superior for thalidomide, but OS
milar
atients with high-risk FISH had
orse OS on thalidomide
Thalidomide/AHSCT PFS 30 mo
Blood and Marrow Transplant Clinical Trials Network; IFM, International
Cooperative Group 65/German Multicenter Myeloma Group HD4; MRC,
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Treatment options for MM relapse post-AHSCT are often
limited by host and/or disease-related factors. Efﬁcacy of
bortezomib and lenalidomide in relapse has been demon-
strated in phase III trials and is reﬂected by improved post-
relapse survival since the introduction of novel agents [1].
Novel agentebased combinations (extensively reviewed
[29]) appear to improve efﬁcacy and can achieve clinically
meaningful responses, as exempliﬁed by results of the
recently reported phase III comparison of thalidomide/
dexamethasone with or without bortezomib for progression
or relapse after AHSCT.
Patients relapsing within 12 to 18 months of AHSCT are at
very high risk for rapid progression and early mortality. Even
when remission can be reinduced, postremission strategies
to prevent subsequent relapse have not been established.
Late relapse after AHSCT (beyond 36 months) has a variable
prognosis, perhaps inﬂuenced by the use of maintenance
therapy. Patients with biochemical MM progression while
receiving lower-dose maintenance have many treatment
options, including use of “treatment” doses of the mainte-
nance agent. In contrast, patients with late clinical relapse and
rapid MM progression may require combination approaches
to reinduce remission, with second AHSCToffering potentially
meaningful clinical beneﬁt.
Outcomes after relapse following current multiagent
inductioneAHSCTeconsolidationemaintenance protocols
have yet to be determined. From the University of Arkansas’
“total therapy” approach, comparison between successive
iterations suggests an overall beneﬁt to upfront use of the
entire therapeutic arsenal, yet it may render subsequent
relapse more difﬁcult to treat [30]. Several new therapeutic
targets have been identiﬁed in MM, and small-molecule
inhibitors as well as novel monoclonal antibodies are in
clinical development for relapse treatment (Table 2). Broadly,
second-generation PIs and IMiDs show promising single-
agent activity, and histone deacetylase inhibitors, phosphati-
dylinositol 3-kinase pathway inhibitors, and cyclin-dependent
kinase inhibitors are being tested in combination with novel
agents.
Salvage second AHSCT is increasingly performed, with
signiﬁcantly greater clinical beneﬁt for those with late MM
relapse [31] (Figure 2) and signiﬁcantly better than salvageTable 2
Newer Agents in Trials for Relapsed MM
Agent Therapeutic Class Com
Drug Compounds
Carﬁlzomib Irreversible PI, intravenous Acce
Ixazomib (MLN9708) Reversible PI, oral Phas
Oprozomib (ONX 0912) Irreversible PI, oral Phas
Marizomib (NPI-0052) Irreversible PI, intravenous Phas
Pomalidomide Novel IMiD, oral Acce
Vorinostat Histone deacetylase (HDAC) inhibitor, oral Phas
Panabinostat (LBH589) HDAC inhibitor, oral Phas
Rocilinostat (ACY-1215) HDAC6-selective inhibitor, oral Phas
AT7519 Cyclin-dependent kinase inhibitor,
intravenous
Phas
Monoclonal Antibodies
Antibody Target Com
Elotuzumab CS1 Phas
Daratumumab CD38 Phas
SAR650984 CD38 Phas
BT062 CD138 Phas
Lorvotuzumab CD56 Phas
Milatuzumab CD74 Phas
FDA indicates US Food and Drug Administration.AlloSCT after AHSCT relapse [32]. In spite of a long-
demonstrated graft-versus-myeloma effect, treatment-
related mortality has signiﬁcantly limited the therapeutic
beneﬁt of AlloSCT for MM; with the use of reduced-intensity
conditioning regimens, treatment-related morbidity and
mortality are modestly reduced, but increased relapse
negates any survival beneﬁt over AHSCT [33]. Several
randomized trials evaluated the tandem AHSCTeAlloSCT
approach to reduce the risk of relapse in the upfront trans-
plantation setting, with discordant results [34-37]. A recent
meta-analysis of the published AHSCTeAlloSCT versus
AHSCT studies concluded that although CR rates are higher
for AlloHCT, neither event-free survival nor OS beneﬁt could
not be consistently demonstrated [38]. Thus, whereas
AlloSCT may be potentially curative, graft-versus-host
disease and treatment-related mortality remain prohibitive.
II. THE PROMISE OF CANCER VACCINES AS POST-
TRANSPLANTATION IMMUNOTHERAPY
The potential promise of cellular immunotherapy in tar-
geting hematologic malignancies is highlighted by the
observation that AlloSCT is uniquely curative for a subset of
patients with relapsed or high-risk disease, with disease
responses to donor lymphocyte infusion suggesting that
lymphocytes mediate the therapeutic effect [39-41]. However,
the lack of speciﬁcity of donor lymphocytes limits response
rates and results in considerablemorbidity andmortality from
graft-versus-host disease, driving efforts to develop a safer
and more effective means of harnessing cell-mediated anti-
tumor immune responses.
A promising alternative immunotherapeutic strategy is the
use of cancer vaccines to educate immune effector cells in an
effort to establish antitumor immunity. The design of an
effective tumor vaccine depends on optimizing antigen
presentation, reversing critical elements of tumor-mediated
immune suppression and preventing re-establishment of
tumor tolerance.
Tumor Vaccines
Tumor cells bear unique antigens that differentiate them
from normal tissues and serve as potential targets for
immune effector cells. Candidate antigens for acute myeloid
leukemia (AML) have included Wilms’ Tumor 1 (WT1)ment
lerated approval by FDA; lower risk of neuropathy
e I and II studies
e I and II studies
e I and II studies
lerated approval by FDA
e II and III studies, with novel agents
e II and III studies, with novel agents
e I and II studies, with novel agents
e I/II study, with bortezomib
ment
e III, with lenalidomide
e II, ongoing
e I studies ongoing, with lenalidomide
e I/IIa (DM-4 conjugate), with lenalidomide and dexamethasone, ongoing
e I (DM-1 conjugate), with lenalidomide and dexamethasone, ongoing
e I/II study (doxorubicin conjugate) ongoing
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Aurora-A [47], PRAME [48], and MUC1 [49]. These antigens
may be shared by the primitive stem cell population,
allowing for the potential targeting of this critical source of
disease relapse. In MM, a variety of tumor-associated anti-
gens has been identiﬁed that may be selectively targeted by
host immunity. These include the cancer testis antigens,
MUC1, HM1.24, CYP1B1, SP17, PRAME, WT1, and heat shock
protein gp96 [50-53]. Despite the presence of antigenic
targets, tumor cells evade immune recognition through the
presentation of antigen in the absence of costimulation and
in the context of inhibitory factors that promote tolerance
and immune escape [54]. In contradistinction, cancer
vaccines are engineered to enhance the presentation of
tumor-associated antigens resulting in antigen-speciﬁc T cell
activation and expansion. A follow-up of a phase I clinical
trial evaluating a WT1 peptide-based vaccine reported 3 of 8
AML patients treated with MRD had remained in remission
for at least 8 years [55].
To enhance effective presentation of tumor-associated
antigens in vivo, DC vaccine strategies have been evaluated.
DCs are potent antigen-presenting cells that can be generated
in large numbers ex vivo; tumor antigens and peptides can be
loaded onto ex vivo generated DCs and used as a tumor
vaccine [56]. Clinical studies have demonstrated successful
expansion of antigen-speciﬁc T cells after administration of
peptide-loaded DC vaccines, with potential implications for
prevention and treatment of relapse [55,57-60].
Vaccine strategies designed to induce T cell responses
directed against an individual antigen are potentially limited
by tumor escape through the down-regulation of the target
antigen. Alternatively, the use of whole tumor cells as
a source of antigen may elicit a broader (ie, polyclonal) T cell
response. One novel approach induces differentiation of DCs
from myeloid leukemia blasts ex vivo in an effort to create
a potent antigen-presenting cell that expresses a panel of
autologous leukemia-derived antigens [61,62]. Potential
concerns include the functional capacity of engineered
antigen-presenting cells in vivo as well as loss of antigens
characteristic of the primitive clone in the process of
differentiation.
The GVAX vaccine (Dana-Farber Cancer Institute Cell
Manipulation Core Facility, Boston, MA) [63] approach uses
tumor cells genetically engineered to express granulocyte
macrophage colony-stimulating factor resulting in recruit-
ment of native DCs to the site of vaccination and their
subsequent processing and presentation of antigens. In
a phase I study, vaccination of patients with high-risk AML
was well tolerated and associated with immune response
and an attendant low risk of relapse [63]. We developed
a vaccine model in which patient-derived AML or MM cells
are fused with autologous DCs such that a broad array of
tumor antigens are presented in the context of DC-mediated
costimulation, resulting in the expansion of both tumor-
speciﬁc helper and cytotoxic T lymphocyte (CTL) pop-
ulations [64,65]. In a phase I study, vaccination of patients
with DC/myeloma fusions was associatedwith the expansion
of myeloma-speciﬁc T cells and resulted in disease stabili-
zation in most patients with advanced disease [66].
Vaccination after AHSCT
A major limitation to developing an effective immuno-
logic and clinical response to vaccination involves the
immunosuppressed milieu characteristic of patients with
advanced malignancy. As such, AHSCT offers a uniqueplatform for examining the efﬁcacy of tumor vaccine therapy.
High-dose chemotherapy results in tumor cytoreduction as
well as immunomodulatory effects of depleting regulatory T
cells and disruption of tumor tolerance. Preclinical models
have demonstrated transient enhanced response to tumor
vaccines in the early period of immune reconstitution after
high-dose chemotherapy [67]. In a phase II clinical trial,
administration of GVAX in conjunction with AHSCT in AML
patients induced antitumor immune responses in most
patients and a reduction in residual disease in a subset [68].
In study of patients with MM undergoing therapy with
AHSCT in conjunctionwith DC/myeloma fusions, vaccination
resulted in the expansion of myeloma-speciﬁc T cells and
conversion from partial to complete responses in a subset of
patients [69]. Of note, the post-transplantation period was
associated with signiﬁcant reduction in circulating regula-
tory T cells. In another study, vaccination with an idiotype-
based vaccine after AHSCT was associated with improved
outcomes as compared with an historical cohort of patients
treated with transplantation alone [70]. Response to vacci-
nation in the post-transplantation period may be augmented
by the administration of lymphocytes activated and
expanded by CD3/CD28 costimulation ex vivo [71-73].
Immunomodulation to Enhance Response to Vaccination
Another approach to increase vaccine potency is the
adjunctive use of immunomodulatory agents, which may
promote expansion of memory T cell populations critical to
durable responses. Tumor-associated factors that inhibit DC
maturation and activation (eg, vascular endothelial growth
factor and indoleamine 2,3 dioxygenase) are potential ther-
apeutic targets to enhance vaccine activity. Ipilumumab
blocks signaling via the negative T cell regulatory checkpoint,
CTLA-4, and has received US Food and Drug Administration
approval as an immunotherapy for advanced-stage mela-
noma [74-76]. Its use is now being explored as a potential
vaccine adjuvant [77]. The programmed cell death ligand 1
(PD-L1)/programmed cell death protein 1 (PD-1) pathway is
a critical mediator of tolerance in the setting of chronic viral
infection and malignancy, by inhibiting both DC-mediated
stimulation of T cells and CTL-mediated killing of tumor
targets [78,79]. PD-1 and PDL-1 directed antibodies are
currently being studied as immunotherapeutic agents.
Preclinical studies have demonstrated that vaccination with
DC/MM fusions in conjunction with PD-1 blockade results in
suppression of vaccine-induced expansion of regulatory T
cells, increased CTL expansion, and enhanced myeloma-
speciﬁc CTL responses [80]. Clinical studies exploring
whether PD-1 blockade can facilitate establishment of
durable vaccine-mediated immune responses are under way.
In summary, tumor vaccines hold promise as means of
eliminating residual disease and preventing disease recur-
rence after AHSCT. Novel immunomodulatory agents and
immune checkpoint blockade may have the potential to
augment vaccine-induced memory T cell responses in vivo.
Although results of preclinical and early-phase clinical
studies show promise, evaluating vaccine efﬁcacy in the
setting of minimal disease is a challenge that ultimately will
require evaluation in the context of randomized clinical trials
with survival endpoints.
III. NK CELL IMMUNOGENETICS: IMPLICATIONS FOR
RELAPSE RISK AND PREVENTION
The role of innate immunity in tumor recognition and
response has been recognized for decades, with the name
D. Avigan et al. / Biol Blood Marrow Transplant 19 (2013) 1661e16691666bestowed to NK cells based on their ability to kill tumor
targets. The clinical importance of this innate surveillance
system for diseased cells (ie, infected, transformed, and
injured cells) was ﬁrst documented in patients who lacked
functional NK activity, whose recurrent viral infections and
lymphoproliferative disorders led to early demise [81,82].
Since the identiﬁcation of the NK cell, investigators have
sought to capture their antitumor effects for the treatment of
cancer. Their efforts, however, were initially slowed by deﬁ-
ciencies in understanding the molecular mechanisms
controlling NK activity, speciﬁcally the receptoreligand rela-
tionships dually responsible for conferring NK effector
potential against nonself targets while simultaneously pre-
venting NK reactivity to autologous cells. This report reviews
the NK cell surface receptors and ligands important for NK
education, highlighting the clinical situations inwhich speciﬁc
NK subsets aremost effective andemphasizingpharmacologic
and genetic approaches to exploit NK antitumor effects.
NK Receptors and Ligands
The NK cell is studded with an array of inhibitory and
activating receptors, with signals that integrate to dictate NK
response. Receptors in humans include the inhibitory and
activating forms of KIR, the CD94/NKG2A heterodimer, the
natural cytotoxicity receptors (NKp46, NKp44, and NKp30),
NKG2D, the signaling lymphocytic activation molecule
(SLAM) receptors, DNAM1, and the Fcg receptor IIIA (CD16).
Although seemingly complex, the receptoreligand relation-
ships can be generally distilled into 2 types: (1) recognition of
self-determinants, such as self-HLA, resulting in NK tolerance
to normal autologous cells and ignorance to tumor cells with
up-regulated HLA; and (2) detection of “stress-induced self
molecules” normally expressed at low levels on normal cells
but up-regulated on infected or transformed cells, resulting in
NK activation and tumor toxicity. In humans, stress-induced
molecules include the NKp30 ligand B7H6 and the NKG2D
ligands MICA, MICB, and ULBP family members. Fine-tuning
the response is the adaptor molecule SAP, which is critical
for the activating properties of the SLAM receptor, particularly
in its response to hematopoietic target cells. In addition,
tumor targets can avoid NK toxicity by expressing class I
molecules and the inhibitory molecule 4Ig-B7H3. A separate
category of NK celletumor interaction occurs through CD16,
whose binding of therapeutic monoclonal antibodies triggers
antibody-dependant cell-mediated cytotoxicity (ADCC).
Diversity of the Functional NK Repertoire
Thus, NK celletumor interactions can involve simulta-
neous mechanisms of NK activation and inhibition signals.
The degree of the NK cell’s response, however, is highly
dependent on its “education” or licensed capacity for killing,
where the molecular interactions most closely linked to
education are between the KIR receptors and their HLA class I
ligands, HLA-C1, HLA-C2, and HLA-Bw4. Not only is interac-
tion between the inhibitory receptor and its self-HLA ligand
important for signaling tolerance to self, it is also required for
the NK cell to achieve functional competence [83], where
high-afﬁnity KIReHLA allotype combinations not only lead
to higher functional capacity but also to greater potency of
inhibition [84]. Expression of receptors occurs stochastically,
leading to a repertoire that is diverse in number and
abundance of receptors on the cell surface. Functionally
translated, this phenotypic diversity results in a continuum
of response to target cells. In addition, KIR and HLA re-
gions segregate independently, leading to frequent geneticcombinationswhere individuals lack 1 ormore class I ligands
for autologous KIR (missing ligand). In these individuals,
unlicensed NK cells expressing inhibitory KIR for nonself HLA
represent a signiﬁcant proportion of the NK repertoire and
are not sensitive to class I expression on the target cell.
Harnessing Autologous NK Effects
An understanding of KIReHLA protein interactions and
their perturbation in various disease states is useful in
designing effective strategies to exploit autologous and
allogeneic NK activity against cancer. Robust NK reconstitu-
tion has been associated with improved outcomes for AML,
non-Hodgkin lymphoma, and MM after AHSCT [16,85],
indicating that NK proliferation agents, such as IL-15, may
enhance antitumor effects. Patients undergoing AHSCT for
various solid tumors experience an improved outcome if the
patient is missing 1 or more KIR ligands [86]. Among these
tumors, high-risk neuroblastoma is particularly informative,
because its treatment typically includes anti-GD2 mono-
clonal antibody therapy, where the primary mechanism of
action is through NK-mediated ADCC. Unlicensed NK cells
expressing KIR for nonself HLA are highly capable of ADCC
with anti-GD2 antibody, whereas licensed NK cells ex-
pressing KIR for self-HLA are inhibited by induced class I
expression on the tumor surface [87]. Because NK cells
mediate ADCC for other monoclonal antibodies in clinical
use, including the anti-CD20 antibody rituximab, it will be
important to establish whether KIReHLA genotypes pre-
dictive of missing ligand are similarly advantageous. Two
novel pharmacologic approaches hold promise in this
setting: monoclonal antibody activation of CD137 to enhance
ADCC [88] and anti-KIR antibodies to interfere with class
Iemediated inhibition of licensed NK cells [89].
New options in the treatment of MM enlist higher NK
activity as mechanisms of their efﬁcacy [90]. PIs decrease
class I expression and up-regulate NKG2D ligand expression
on myeloma cells, and IMiDs such as lenalidomide enhance
NK function through induced Tcell production of IL-2, down-
regulation of PD-L1, increased natural cytotoxicity, and
heightened ADCC. Promising new approaches include the
anti-PD1 antibody and the anti-inhibitory KIR antibody to
overcome inhibitory signaling from the myeloma target, as
well as the anti-CD1 monoclonal antibody, which targets
CD1-expressingmyeloma cells and recruits NK cells for ADCC
activity.
Capturing Allogeneic NK Effects
The ﬁrst clinical setting to harness the potential of the
allogeneic NK cell was HLA-mismatched HSCT, where allor-
eactive donor NK cells stimulated by missing self demon-
strated potent effects against AML [91]. Since then, it has
become clear that donor NK alloreactivity can occur in the
HLA-matched setting as well. Cytokine-enhanced activity of
unlicensed NK cells [92] likely contributes to reduced AML
relapse among patients lacking any KIR ligand [93] and not
just ligands present in the donor. Donor-activating KIR are
also associated with reduced relapse [94] and decreased
mortality [95]. Activating KIR, however, are not all similar.
KIR2DS1, the only activating KIR for which a ligand is known,
is important in NK education and tolerance, and KIR2DS1-
positive cells from HLA-C2 homozygous individuals have
reduced function compared with KIR2DS1-positive cells
from HLA-C1 individuals [96]. Translated to the clinical
setting, KIR2DS1-positive donors are associated with lower
relapse in AML patients, but only if the donor is not HLA-C2
D. Avigan et al. / Biol Blood Marrow Transplant 19 (2013) 1661e1669 1667homozygous [97]. The possibility of improving trans-
plantation outcomes by incorporating KIR gene and allele
typing into donor selection algorithms is now real, and
prospective trials demonstrating the effectiveness of donor
KIReHLA gene proﬁling in donor selection will be an
important step in broadening the frontiers of
transplantation.
FUTURE DIRECTIONS AND RESEARCH PRIORITIES
A major achievement of the National Cancer Institute’s
Second International Workshop on the Biology, Prevention,
and Treatment of Relapse after Hematopoietic Stem Cell
Transplantation was the establishment of an international
consortium of investigators with the objective of conducting
collaborative research in the ﬁeld of relapse after HSCT. This
session highlighted the far-reaching effects of novel agents
and immunomodulatory interventions on the clinical mani-
festations of relapse and the implications for possible relapse
prevention and treatment trials. The discussions identiﬁed
opportunities to deﬁne and therapeutically exploit areas of
common as well as distinct biology between the allogeneic
and autologous SCT platformsdand the potential to improve
treatment outcomes in both.
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